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1. Introduction 
1.1 Metabolic pathway 
Methionine is one of four amino acids that form succinyl CoA. This sulphur containing 
amino acid is the source of homocysteine (Hcy). It is converted to S-adenosylmethionine 
(SAM), the major methyl-group donor in one–carbon metabolism. The synthesis of SAM 
occurs when methionine condenses with adenosine triphosphate (ATP) by the hydrolysis of 
all three phosphate bonds. The methyl group attached to the tertiary group in SAM is 
activated and can be transferred to a variety of acceptor molecules, such as noradrenaline in 
the synthesis of adrenaline. The reaction product S-adenosylhomocysteine (SAH) is a simple 
thioether, analogous to methionine. The resulting loss of free energy accompanying the 
reaction makes the methyl transfer essentially irreversible. Next is the hydrolysis of SAH to 
Hcy and adenosine. Homocysteine has two fates. If there is a deficiency of methionine, Hcy 
may be re-methylated to methionine. If stores of methionine are adequate, Hcy may enter 
the trans-sulphuration pathway, where it is converted to cysteine. The re-synthesis of 
methionine occurs with the acceptance of a methyl group from N5-methyltetrahydrofolate 
(N5-methyl-THF) in a reaction that requires methyl-cobalamin, a coenzyme derived from 
cobalamin (vitamin B12). The methyl group is transferred from the B12 derivative to Hcy, 
and vitamin B12 is recharged from N5-methyl-THF. The synthesis of cysteine occurs when 
Hcy combines with serine, forming cystathionine, which is hydrolysed to α - ketobutyrate 
and cysteine. This sequence has the net effect of converting serine to cysteine and Hcy to α - 
ketobutyrate, which is oxidatively decarboxylated to form propionyl CoA. Because Hcy is 
synthesised from the essential amino acid methionine, cysteine is not an essential amino 
acid so long as methionine is available (Figure 1). 
Under normal metabolic circumstances, there is a strict balance between Hcy formation and 
elimination. Usually about 50% of the Hcy formed is re-methylated to methionine. When 
protein or methionine intake is in excess, the trans-sulfuration pathway catabolises a larger 
proportion. If there is an increased formation of Hcy relative to its consumption, Hcy is 
excreted from the cells. This can be detected as an increased level of Hcy in plasma/serum 
or in the urine. 
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Fig. 1. Homocysteine Metabolism 
1.2 Genetic influences 
Homocysteine metabolism therefore has three key enzymes (Figure 1); 
methylenetetrahydrofolate reductase (MTHFR), cystathionine beta-synthase (CBS) and 
methionine synthesase (MTR).  
The key enzyme in the remethylation pathway is MTHFR. Single nucleotide polymorphisms 
have been identified for this enzyme. The common C å T substitution at the 677 position 
results in decreased enzymatic function. This alanine to valine substitution, in 
heterozygotes, causes a 30% drop in function, and with homozygotes, a 60% reduction.1 
Deficiency of CBS deficiency likewise causes hyperhomocysteinaemia (HHcy), but the 
severity is less compared with vitamin B12 deficiency. This suggests the CBS enzyme is not 
as central to the total homocysteine (tHcy) level as the MTHFR enzyme.  
The effect of the MTHFR genetic polymorphism has been scrutinized in a placebo controlled 
trial.2 The TT homozygous group for the mutation had a 2.4 times greater reduction in tHcy 
compared to wild type after 1mg of folic acid was given daily for three months, owing to the 
elevated baseline tHcy of TT group compared to CC and CT subgroups. This means MTHFR 
TT groups can be targeted for therapy. However, a British study3 of an older population 
described a regional difference in the tHcy even after adjustments for folate and vitamin B12 
levels, smoking and the effect C677T polymorphism. This can only be explained by the effect 
of other unidentified genetic, systemic or environmental factors. 
A secondary mutation of the MTHFR gene at position 1298 AåC also reduces function. 
Alone, this mutation confers no difference in the tHcy, but in combination with the 677 CåT 
mutation, unsurprisingly, there is an elevation in the tHcy and decreased folate levels.4 
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1.3 Systemic and environemental influences 
The effect of systemic disease, medications and environmental exposures on Hcy has been 
described in detail.5 A summary is provided in Table 1. 
 
Reduced tHcy Moderate  
(15-30µmol/L) 
Intermediate  
(30-100µmol/L) 
Severe  
(>100µmol/L) 
Down syndrome 
Pregnancy 
Folate excess 
B12 Excess 
B6 Excess 
Hyperthyroidism 
Diabetes Mellitus 
Exercise 
MTHFR CåT 
homozygosity 
Male 
Post-menopausal 
Smoking 
Coffee 
Alcohol 
Diabetes Mellitus 
 
 
Folate deficiency 
 
Renal failure 
 
 
Homocystinuria 
 
Vitamin B12 
deficiency 
Table 1. Environmental and Systemic Influences on Homocysteine. 
2. Homocysteine assays 
Accurate measurement of Hcy requires a working knowledge of the plasma distribution. 
The vast majority is protein bound; the rest is free. This is further subdivided into Hcy–
cysteine mixed disulphide, homocystine and Hcy. In combination they are tHcy.  
Three types of assays have been used in Hcy-glaucoma studies: high performance liquid 
chromatography (HPLC), enzyme-linked immunoassays (EIA) and fluorescence 
polarization immunoassays (FPIA). The latter 2 give an estimation of the tHcy and are 
relatively easy to perform.5 In contrast, HPLC is more difficult to run and may have a much 
lower through put, but has the advantage of a broader analytical range and lower cost per 
test. Results from all 3 are comparable although there can be significant differences between 
methods and even between laboratories using the same method.6 Strategies to reduce the 
influence of inter-test variability should include running case and control assays 
simultaneously and using a single laboratory. Many Hcy-glaucoma studies have employed 
single laboratories but it is unclear whether testing was grouped or random. No method has 
demonstrated superiority over another. 
3. Homocysteine and systemic disease 
Injury to vascular endothelium, retinal ganglion cell apoptosis and extra-cellular matrix 
(ECM) remodelling of trabecular meshwork and/or lamina cribrosa may all contribute to 
optic nerve damage characteristic of glaucoma.  All three events are linked with Hcy: the 
evidence is presented below. 
3.1 Cardiovascular disease 
In 1969, McCully7 highlighted a potential link between Hcy and cardiovascular disease 
(CVD) by observing pathological changes to blood vessels in 2 children. In both cases, gross 
vascular damage to arteries (small, medium and large); focal narrowing due to intimal and 
medial fibrosis and focal proliferation of peri-vascular connective tissue in the small vessels 
was noted in the setting of raised Hcy and cystathione. Since then, further animal and 
www.intechopen.com
 The Mystery of Glaucoma 
 
44
human research has shown a link between tHcy elevation and bioavailablity of 
endothelium-derived nitric oxide.8 Endothelium dependent vasodilation is significantly 
impaired in subjects with HHcy compared to controls.9 The early pathogenesis of 
atherosclerosis is related to this impairment of vasodilation, and HHcy exacerbates this. 
Even in healthy adults, a methionine load that produces transiently raised tHcy levels, 
impairs flow mediated endothelium dependent vasodilation.10 
In vitro, it has been demonstrated that HHcy may cause vessel dysfunction via induced 
endothelial apoptosis. Apoptotic cell death in the endothelium via the unfolded protein 
response 11 and the detachment-mediated process12,13 are two possible mechanisms.  
HHcy as a cardiovascular risk factor remains a contentious issue however. Observational 
studies have shown HHcy to be associated with an increased CVD risk,14-17 though a causal 
role has been more difficult to confirm. A meta-analysis examining risk of ischaemic heart 
disease (IHD) and stroke found Hcy only a modest predictor in healthy populations.18 With 
a 25% reduction in Hcy an 11% reduction in IHD and 19% reduction in stroke would occur if 
prospective data was used (the meta-analysis used retrospective data that may have 
suffered from reverse-causality) in the presence of adjustment for other known CVD risk 
and correction for regression dilution bias is performed.  
Several randomized control trials (RCTs) on therapeutic reduction of Hcy in cardiovascular 
disease have been conducted; they typically use folate, vitamin B6 and B12 supplements as 
intervention. A meta-analysis of RCTs shows no significant difference between intervention 
and control groups.19 Another large study20 did not show a benefit in taking B group 
vitamins and folate verses placebo in those who has suffered a cerebrovascular event 
(ischaemic stroke, transient ischaemic attack or intracerebral haemorrhage). There was no 
reduction in the relative risk for non-fatal / fatal stroke, myocardial infarction or any other 
death from a vascular cause. The meta-analysis by Bazzano et al21 similarly found all-cause 
mortality as well as CVD was not improved with folic acid supplementation amongst those 
with a prior history of vascular disease. 
3.2 Homocysteine and apoptosis  
As mentioned, evidence that Hcy induces vascular endothelial cell apoptosis exists.11-13 
Similar findings have been reported in neuronal tissue experiments as well. For example, 
Hcy stimulation of the N-methy-D-aspartate (NMDA) receptor of cerebellar granule cells 
has been shown to induce their death.22 Importantly, this finding has been replicated for 
retinal ganglion cells (RGC). Moore et al23 have shown intravitreal injection of homocysteine 
causes RGC apoptosis in vivo. Higher doses of homocysteine were associated with more 
widespread RGC apoptosis. In more recent work, Ganapathy et al24 assessed mouse RGC 
cell culture response to Hcy exposure. They found marked RGC apoptosis in the presence of 
Hcy, a response that was significantly reduced by co-application of MK-801 (NMDA-
receptor blocker). Homocysteine was also found to significantly increase intracellular 
calcium as well as reactive species superoxide, nitric oxide and peroxynitrite.  
These studies in themselves do not constitute direct evidence that Hcy causes neuronal 
apoptosis. They do however suggest Hcy has the potential to do so through activation of 
NMDA-mediated intracellular pathways. Strategies that target Hcy and/or NMDA-
receptors may potentially block this response and have therapeutic potential in glaucoma. 
Further work is need in this area. 
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3.2.1 Dementia and neurodegeneration 
Given chronic glaucoma is characterised by progressive RGC apoptosis, it may be 
considered a form of neurodegeneration. Both chronic glaucoma and other 
neurodegenerative diseases, such as Alzheimer’s disease (AD), similarly occur in 
predominantly elderly populations. A common aetiology is possible.  
It is interesting to note the recent observation that Hcy is a biomarker for neurodegenerative 
disease and useful in identifying patients with B vitamin deficiency.25 It has been shown that 
clinical symptoms of cognitive impairment and missing ankle tendon jerks are associated 
with patients with low vitamin B12 concentrations.26  
A recent cohort study has demonstrated a correlation between polyneuropathy or dementia 
and increased tHcy in a geriatric population.27 Similar findings were reported in an earlier 
study of neurodegenerative disorders, thus raising the possibility that Hcy has neurotoxic 
effects. These findings are consistent with laboratory data demonstrating neuronal apoptosis 
induced by Hcy as discussed above. However, given the apparent association between Hcy 
and CVD plus the role vascular disease plays in dementia and polyneuropathy,28 it is 
difficult to know whether HHcy is causal or merely an association.   
Evidence in support of a causal relationship between Hcy and neurodegeneration comes 
from a study examining central nervous system (CNS) atrophy with magnetic resonance 
imaging.29 Patients aged over 70 years with mild cognitive impairment were randomised to 
receive either high-dose folic acid, vitamins B6 and B12 (n=85) or placebo (n=83) for 2 years. 
The mean rate of CNS atrophy per year was 0.76% [95% CI, 0.63–0.90] in the active 
treatment group and 1.08% [0.94–1.22] in the placebo group (P = 0.001). The treatment 
response was related to baseline Hcy levels: the rate of atrophy in participants with Hcy >13 
µmol/L was 53% lower in the treatment group (P = 0.001). Whether the findings result from 
reduced Hcy, neuroprotective effects of folic acid, vitamin B6 and/or vitamin B12, improved 
CNS blood flow or some other mechanism is not clear. It does, however, raise the possibility 
that Hcy is involved in the neurodegenerative process.  
3.2.2 Extracellular matrix remodelling 
Extracellular matrix remodeling by Hcy is interesting because of implications for glaucoma 
pathogenesis. Effects on vascular tissues of the optic nerve head in addition to the trabecular 
meshwork or lamina cribrosa could result in glaucoma development or progression. There 
is no evidence to directly support this theory but findings in non-ocular tissue suggest a 
potential role. Human vascular smooth muscle cells from cardiomyopathic hearts 
demonstrate premature atherosclerosis when exposed to Hcy.30 This is in association with 
significant up-regulation of collagen expression and α-actin. The response is potentially 
mediated through induced matrix metalloproteinase (MMP)-2, -4 and -9 activity as well as 
increased nitrotyrosine expression.31-33  
4. Homocysteine and ocular vascular disease 
Although the exact pathogenesis of glaucomatous optic neuropathy is unknown, impaired 
blood flow to the optic nerve head may play a role.34,35  
Compromised optic nerve head perfusion may, in part, be due to the action of plasma Hcy. 
Raised tHcy causes overproduction of free radicals, intimal damage, matrix 
metalloproteinase up regulation and lysis of elastin or collagen in arterial media. 36,37 These 
effects are strongly linked with systemic vasculopathy including coronary artery disease, 
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aortic aneurysm, peripheral vascular disease and stroke. Similar events are likely to affect 
the microcirculation of the eye, including the optic nerve head. 
Such associations have been described for a number of ocular vascular conditions. These are 
summarized below.  
4.1 Retinal artery and vein occlusion 
There have been numerous studies examining the association between raised plasma Hcy 
and retinal vascular occlusions. For instance, Moghimi et al38 have demonstrated in an 
Iranian population, elevated plasma Hcy in retinal vein occlusion compared to control 
(14.76 vs 11.42 µmol/l). This is similarly the case in Indian,39 North American,40 Italian41 and 
Chinese42 studies. These findings are supported by data from the Blue Mountains Eye Study 
(Australia) demonstrating a significant correlation between vein occlusion and Hcy.43 
Meta-analysis of Hcy in retinal vein occlusion has recently been performed.44 In all,  
there were 1533 cases of retinal vein occlusion and 1708 controls where plasma Hcy was 
assessed. Individuals with vein occlusion had, on average, tHcy 2.8 µmol/L higher than the 
control group. It was concluded that evidence supports the role of Hcy in retinal vein 
occlusion but that publication bias and study heterogeneity were potential confounders. As 
for the cause for HHcy in these patients, the reason was not clear. The role of MTHFR 
mutation was examined but no correlation found. Environmental factors are likely to be 
important. 
The literature on Hcy and retinal artery disease largely consists of small studies with fewer 
than 50 patients. One of the largest is a retrospective study of 105 patients with retinal artery 
occlusion.45 This study found significant elevation of tHcy compared with the same number 
of controls. Mutation of MTHFR was also examined but no significant association could be 
found. Other notable studies46,47 have reported similar findings and population based 
analysis from the Blue Mountains Eye Study also suggests HHcy and retinal artery emboli 
are weakly associated.48 A small meta-analysis49 suggests HHcy is more common in retinal 
artery occlusion but again no correlation with MTHFR mutation was found. 
4.2 Choroidal neovascularization 
Choroidal neovascularization (CNV), as seen in age-related macular degeneration (AMD), is 
a process of vascular proliferation beneath the retinal pigment epithelium and sub-retinal 
space. Risk factors are numerous and include cigarette smoking, lack of exercise, low fruit 
consumption, hypercholesterolaemia, increasing age and genetic susceptibility (eg: 
compliment factor H).50,51 
A comprehensive epidemiological review shows links between CVD and AMD.52 Analysis 
of data from the Framingham Eye Study and Beaver Dam Study, provides evidence that 
CVD and AMD share a similar risk profile (such as age, smoking, hypertension, 
hypercholesterolemia, post-menopausal estrogen use, diabetes, and dietary intake of fats, 
alcohol and antioxidants). In the same analysis, Hcy and vitamin B compounds were 
independent risk factors for both CVD and AMD. 
Homocysteine as a risk factor for CNV development has been confirmed in a number of 
studies. Axer-Siegel et al53 reported a significantly increased frequency of HHcy in patients 
with neovascular AMD (44.1%) compared to dry AMD (22.4%) and age-matched controls 
(21.4%). Several other groups have confirmed this finding.54,55 
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4.3 Diabetic retinopathy 
The Wisconsin epidemiological study of diabetic retinopathy,56 spanning from 1979 until 
2007, looked at patients with type 1 diabetes mellitus. In the 1990-1992 prevalence data, Hcy 
was associated with increased odds of more severe diabetic retinopathy and presence of 
macular oedema. Many studies since have confirmed this association for type 2 diabetes 
mellitus as well.57-59  
It is also true that severity of retinopathy correlates strongly with Hcy level, independent of 
glycaemic control.60 Higher Hcy levels are observed in individuals with proliferative 
retinopathy compared to non-proliferative retinopathy, even though in both instances the 
levels are significantly elevated compared to control. This occurs despite similar baseline 
plasma glucose measurements and comparable frequencies of CVD (hypertension, 
ischaemic heart disease, cerebrovascular accident, thromboembolic event). 
More recently, plasma and vitreous Hcy has been measured in patients with proliferative 
diabetic retinopathy.61 Samples taken at the time of intra-ocular surgery showed mean 
elevation of both Hcy sample groups (plasma 16.04 ± 2.75 µmol/L; vitreous 3.64 ± 0.65 
µmol/L) compared to non-diabetic controls. This both supports the outcomes of other 
studies on tHcy in diabetes and provides evidence of impaired blood-retina barrier in these 
patients. It is unclear what effect elevated vitreal Hcy has on disease progression. 
There is conflicting evidence on the role of MTHFR mutation as a determinant of HHcy in 
diabetic retinopathy. A large study in Chinese patients62 showed the MTHFR T allele was 
present in 49.09% of cases with diabetic retinopathy. This was significantly higher than in 
individuals with diabetes without retinopathy (33.16%) or no diabetes at all (31.58%). It has 
been suggested that homozygous mutation of MTHFR is associated with premature onset of 
diabetic retinopathy only in the presence of homozygous methionine synthase reductase 
mutation.63 However, in a case series from Turkey,64 no association between MTHFR C677T 
mutation and HHcy with retinopathy or neuropathy could be found. It is unclear whether 
such differences reflect ethnic variation, result from differences in study design or are 
influenced by other unidentified factors. 
4.3.1 Non-Arteritic Ischaemic Optic Neuropathy (NAION) 
In terms of pathophysiology, non-arteritic ischaemic optic neuropathy (NAION) and 
chronic glaucoma share a common mechanism. Both display deficiencies in optic nerve head 
perfusion although the mechanism is much less certain with chronic glaucoma. The event in 
NAION may represent a watershed infarct of retro-laminar optic nerve head tissue in 
individuals with compromised short posterior ciliary arteries and risk factors that include a 
crowded disc, poorly overlapping vascular fields, nocturnal hypotension and hypoxia.65 
Some risk factors are common to chronic glaucoma and typically ante cede both conditions 
by many years. However, whilst NAION is an acute condition, chronic glaucoma is not. 
Given that impaired circulation is central to the development of NAION, it seems logical 
that HHcy might play a role. This has borne out in several studies examining associations 
between the two. Pianka et al66 reported elevated levels in 45% of 40 NAION patients (mean 
age 66 years) but in only 9.8% of control subjects. Similar findings have been reported by 
Giambene et al67 and Weger et al.68 
However, some studies have questioned the association. Both Kawasaki et al69 in a study of 
17 patients and Biousse et al70 in a study of 14 patients failed to find any significant 
association with Hcy. One might criticise these studies on the basis of small participant 
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numbers but it is noteworthy that both patient cohorts were relatively young. This is 
interesting given plasma Hcy levels increase with age.5 This raises the possibility that Hcy 
becomes increasingly important in NAION development with increasing age and again 
points to similarities with chronic glaucoma. Further research is required in this area.  
4.4 Ocular Ischaemic Syndrome 
Ocular ischemic syndrome (OIS) is the name given to the ocular symptoms and signs 
attributable to chronic, severe carotid artery obstruction, although chronic ophthalmic artery 
obstruction can cause a similar clinical picture. Atherosclerosis is the most common 
aetiology, but possible causes include Eisenmenger syndrome, giant cell arteritis, and other 
inflammatory conditions. Most patients are older than 55 years of age. Typically, a 90% or 
greater ipsilateral obstruction is necessary to cause the ocular ischemic syndrome. Both eyes 
are involved in about 20% of cases.  Iris neovascularization is the most common anterior 
segment finding at diagnosis and typical fundus signs include retinal arteriole narrowing, 
retinal venous dilatation without tortuosity, midperipheral retinal haemorrhages and 
microaneurysms, and peripheral vascular closure. 
Little information is available linking OIS with HHcy. A case described of bilateral OIS71 
without carotid artery stenosis and normal cardiovascular and biochemical markers had a 
markedly elevated tHcy of 20.8 µmol/l as the only abnormality. No larger studies have been 
published to confirm or deny this association. 
5. Plasma homocysteine and chronic glaucoma 
Chronic glaucoma may, in part, be the manifestation of abnormal optic nerve head 
perfusion. This is supported by evidence showing altered flow dynamics within the 
ophthalmic and retinal arteries of patients with glaucoma, an association between glaucoma 
and vascular disease, and acceleration of the glaucomatous process in the presence of 
nocturnal hypotension. Evidence also indicates glaucoma is a process of retinal ganglion cell 
apoptosis, which may in turn be related to or independent of optic nerve head perfusion.  
Homocysteine potentially contributes to glaucoma pathogenesis via both mechanisms. 
Unsurprisingly, many studies have examined the role of Hcy in glaucoma over the past 
decade. However, there are inherent difficulties in comparing studies on tHcy. The work in 
relation to glaucoma is no exception. The main challenges relate to the way Hcy is 
measured, study design and differences in populations studied.   
Despite the large number of Hcy-glaucoma studies, collectively they report on a relatively 
confined population. A significant number of studies have been in Turkish cohorts. German 
studies also contribute significantly to the overall number. The German studies are from the 
same group and presumably represent the same population. 
There are also reports from Israel, Australia, USA, Italy and Pakistan. We have no results 
from populations in Asia, Africa or South America. Interestingly, there is also little data 
published from Scandinavia. Given the findings in pseudoexfoliation glaucoma (PXFG) and 
high prevalence of PXFG in this region, one would expect both interest and opportunity to 
conduct studies there. There has been a report on tHcy in pseudoexfoliation syndrome and 
PXFG combined from Finland;72 we are not aware of any studies specifically reporting 
glaucoma. 
The main determinants of mildly elevated plasma homocysteine remain poor diet, 
vegetarianism, low folate, low cobalamin, MTHFR mutation, renal impairment and 
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medications5. Whilst the majority of Hcy-glaucoma studies control for the effects of 
medication and renal impairment, much less is known about the caloric intake of the study 
participants or folate/cobalamin status. Differences in diet are likely to be real but the 
impact is unknown in glaucoma research. 
A few studies have reported folate and vitamin B status and point to significant differences 
between populations. Participants in an Italian study73 were found to have high normal 
folate and mid normal vitamin B12 whereas 2 studies from Turkey have low normal vitamin 
B12 with normal74 or depleted folate.79 In at least 1 of these studies,74 it is clear that some 
participants were vitamin B12 deficient as well. As the influence of folate and vitamin B12 
on plasma homocysteine is non-linear,5 these differences could amount to considerable 
variations in plasma homocysteine. For example, vitamin B12 in the mid normal range is 
associated with mean plasma homocysteine around 10 – 11 µmol/L compared to 14 µmol/L 
for vitamin B12 at the lower limit of normal.5 Individuals that are vitamin B12 deficient can 
have plasma homocysteine near 20 µmol/L. Similarly, the difference in folate levels 
reported by Turgut74 and Cumurcu78 can amount to an almost doubling of plasma 
homocysteine.5 Despite researchers best efforts, we are not comparing like with like.   
Only a handful of the reports on Hcy and glaucoma are sufficiently powered to detect the 
outcome they describe.  Sample size calculation, assuming the need to detect a 2 µmol/L 
difference, standard deviation of 3 µmol/L, a power of 90% and significance set at 0.05, 
requires a sample size of at least 48 cases per group. In studies where standard deviation 
exceeds 9 µmol/L (Table 2), 426 cases would be required to detect a significant difference. 
Clearly, these criteria have not been met in most studies. 
 
Author Year Design Number Location Assay 
Homocysteine 
(µmol/L) 
Elevated 
Tranchina73 2011 Prospective 36 Italy EIA 16.55 ± 7.23 Yes 
Turgut74 2010 Prospective 34 Turkey HPLC 15.46 ± 9.27 Yes 
Clement75 2009 Prospective 48 Australia FPIA 11.77 ± 4.18 Yes 
Roedl76 2007 Prospective 30 Germany HPLC 14.51 ± 4.43 Yes 
Roedl77 2007 Prospective 70 Germany HPLC 13.77 ±  4.13 Yes 
Cumurcu78 2006 Prospective 24 Turkey EIA 14.88 ± 3.26 Yes 
Saricaoglu79 2006 Prospective 20 Turkey EIA 18.50 ± 4.50 Yes 
Turacli80 2005 Prospective 60 Turkey FPIA 15.76 ± 5.55 No 
Altinta81 2005 Prospective 22 Turkey FPIA 14.96 ± 4.55 Yes 
Bleich82 2004 Prospective 29 Germany EIA 15.53 ± 7.76 Yes 
Leibovitch83 2003 Prospective 30 Israel HPLC 16.80 ± 3.20 Yes 
Vessani84 2003 Prospective 50 USA FPIA 10.1* Yes 
Bleich85 2002 Prospective 19 Germany EIA 11.61± 3.74 Yes 
* Standard Deviation not reported 
Table 2. Homocysteine and Pseudoexfoliation Glaucoma (PXFG) 
5.1 Pseudoexfoliation glaucoma  
Pseudoexfoliation syndrome is a multi-system disorder of cellular metabolism resulting in 
random synthesis of extracellular fibrillar material. The main clinical manifestation is in the 
eye where fibrillar material can be seen on the lens capsule and pupil margin. Affected 
individuals have a weak lens capsule and zonules and have poor mydriasis. They are at 
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significant risk of developing raised IOP with associated glaucoma (PXFG) but glaucoma 
has also been reported despite apparently normal IOP.  
PXFG shares many common associations with homocysteine. Cardioavascular disease 84, 
oxidative stress87 increased prevalence with age and Alzheimer’s disease 88,89 are common to 
both: a pathogenic link has been proposed.90 This is supported by research showing 
exfoliation material contains laminin, elastin and fibrillin, components of extracellular 
matrix metabolism under the influence of homocysteine. 
All studies looking at the association between PXFG and plasma homocysteine have 
demonstrated significant elevation with the exception of Turacli et al80 (Table 2). This is the 
most consistent finding in homocysteine-glaucoma research and has occurred despite 
different assays and study populations across four continents. The control group in the 
Turacli et al study had the highest mean plasma homocysteine level (17.43 µmol/L; 67.6% 
with hyperhomocysteinaemia) of any study on glaucoma reported in the literature. Clearly 
this rate of hyperhomocysteinaemia in the general population is abnormal and makes 
detection of homocysteine elevation difficult in different cohorts.  
The findings in PXFG are strongly suggestive that Hcy is a factor in its pathogenesis. 
Attention should shift now towards larger population-based studies and clinical trials to 
confirm this association and assess response to intervention (folate and vitamin B12). The 
prospect of an intervention that is taken orally, is cheap and with few side effects is an 
exciting prospect.  
5.2 Primary open angle glaucoma 
Studies are divided on the issue of plasma Hcy and POAG (Table 3). Equal numbers report a 
statistically significant correlation or no correlation at all. It is suggested that differences in 
Hcy assays, study design and populations sampled underlie these outcomes. The effect of 
assays can largely be discounted for 3 reasons: i) HPLC, EIA and FPIA are comparable tests,5 
ii) in each study POAG and control samples were analyzed using the same technique and 
laboratory, and iii) the findings for PXFG have been so consistent despite the use of different 
assays.  
 
Author Year Design Number Population Assay
Homocysteine 
(µmol/L) 
Elevated 
Tranchina73 2011 Prospective 40 Italy EIA 13.91 ± 3.61 No 
Turgut74 2010 Prospective 34 Turkey HPLC 11.28 ± 4.80 No 
Michael90 2009 Prospective 70 Pakistan EIA 15.20 ± 1.28 Yes 
Clement75 2009 Prospective 36 Australia FPIA 11.21 ± 2.84 Yes 
Roedl91 2008 Prospective 36 Germany HPLC 13.43 ± 3.53 Yes 
Roedl92 2007 Prospective 39 Germany HPLC 13.93 ± 4.59 Yes 
Cumurcu78 2006 Prospective 25 Turkey EIA 9.22 ± 3.70 No 
Altinta81 2005 Prospective 19 Turkey FPIA 11.91 ± 4.38 No 
Wang93 2004 Retrospective 55 USA HPLC 14.90 ± 6.45 No 
Bleich85 2002 Prospective 18 Germany EIA 12.52 ± 3.62 Yes 
Table 3. Homocysteine and Primary Open Angle Glaucoma (POAG) 
It is however, quite reasonable to suggest study design and population sampled are 
significant factors. Given the sample size calculations already mentioned, it seems hardly 
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surprising some studies have had a negative outcome. In this respect, it is interesting to note 
that 3 of 5 studies reporting no significant association actually demonstrated small78 or 
considerable74,81 differences in plasma homocysteine between POAG and control. This is 
confounded by large variance in the population (as shown by standard deviation) and high 
mean plasma homocysteine in controls.  
5.3 Normal tension glaucoma 
Non-IOP dependent factors are of particular interest in normal tension glaucoma (NTG). 
Work has focused on optic nerve head perfusion and its influences including atherosclerotic 
disease, systemic hypertension, use of anti-hypertensive agents and vasospastic disorders 
(eg: migraine, Raynaud’s phenomenon). Similarly, retinal ganglion cell apoptosis might play 
a role. Homocysteine has the potential to contribute to NTG pathogenesis via both 
pathways: as a mediator of vascular injury leading to impaired optic nerve head perfusion 
and as an excitatory amino acid triggering RGC apoptosis.23,24 
Five studies have reported on plasma homocysteine in NTG (Table 4). With the exception of 
Clement et al,75 none have found a statistically significant association. However, closer 
examination of these data is needed. Both Turgut et al74 and Cumurcu et al78 reported 
increased plasma homocysteine in NTG though it did not reach statistical significance. 
Levels in NTG were 29.8% and 23.7% higher than control compared to 19.6% as reported by 
Clement et al. Again, sample size plays a role here. Both studies are significantly 
underpowered to detect a difference given the high standard deviation reported.  
It may be the case that homocysteine is not associated with NTG. However, based on the 
scope and quality of research currently available, no conclusions can be made yet. Further 
work is needed to clarify this issue. 
 
Author Year Design Number Population Assay 
Homocysteine 
(µmol/L) 
Elevated 
Rossler94 2010 Prospective 42 Germany FPIA 10.95 ± 2.65 No 
Turgut74 2010 Prospective 48 Turkey HPLC 11.27 ± 4.91 No 
Clement75 2009 Prospective 34 Australia FPIA 11.74 ± 3.79 Yes 
Cumurcu78 2006 Prospective 19 Turkey EIA 10.39 ± 3.89 No 
Vessani84 2003 Prospective 25 USA FPIA 9.1* No 
* Standard Deviation not reported 
Table 4. Homocysteine and Normal Tension Glaucoma (NTG) 
5.4 Primary angle closure glaucoma 
The proposed mechanism by which raised homocysteine contributes to primary angle 
closure glaucoma (PACG) differs significantly from PXFG, POAG and NTG. Much less 
emphasis has been placed on the role of homocysteine in ocular circulation, RGC apoptosis 
and trabecular meshwork remodelling. Instead, the effect on extracellular matrix 
remodelling of other anterior segment structures has been promoted.90 This is on the basis 
that patients with PACG have reduced MMP-2 and MMP-9 expression in Tenon’s capsule 
and Hcy has demonstrable effects on MMP expression.  
The only study reporting plasma Hcy in PACG (Table 5) showed significant elevation 
compared with POAG and control.90 The same report demonstrated increased frequency of 
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C677T and A1298C MTHFR polymorphisms. However, closer analysis shows MTHFR 
mutations are frequent in 1 ethnic group (Punjabi) but not the other (Pathan). Unfortunately, 
Hcy levels within each ethnic group are not stated. A difference between the two would 
suggest i) Hhcy is not associated with PACG but may occur in parallel in some populations 
due to certain factors (eg: MTHFR polymorphisms) ii) the anterior segment remodelling 
theory is unlikely. In the absence of such data we can only speculate. We await other studies 
with interest. 
 
Author Year Design Number Population Assay 
Homocysteine 
(µmol/L) 
Elevated 
Michael90 2009 Prospective 48 Pakistan EIA 20.8 ± 4.8 Yes 
Table 5. Homocysteine and Primary Angle Closure Glaucoma (PACG) 
6. MTHFR mutation and chronic glaucoma 
MTHFR mutation is of interest given its role as the major genetic determinant of raised 
plasma Hcy. Increased mutation rates could help explain the finding of raised plasma Hcy 
in some glaucoma patients. Studies have reported on the frequency of MTHFR C677T 
mutation, and to a lesser extent A1298C, in different types of glaucoma (Table 6). 
 
Author Year Glaucoma Increased Frequency 
Clement75 2009 PXFG No 
Fan95 2008 PXFG No 
Fingert96 2006 PXFG No 
Mossbock97 2006 PXFG No 
Fan98 2010 POAG No 
Michael90 2009 POAG No 
Clement75 2009 POAG No 
Michael99 2008 POAG No 
Zetterberg100 2007 POAG No 
Mabuchi101 2006 POAG No 
Fingert96 2006 POAG No 
Mossbock97 2006 POAG No 
Junemann102 2005 POAG Yes 
Bleich85 2002 POAG Yes 
Clement75 2009 NTG No 
Woo103 2009 NTG Yes 
Mabuchi101 2006 NTG No 
Michael90 2009 PACG Yes 
Michael99 2008 PACG Yes 
Table 6. MTHFR Mutation and Chronic Glaucoma 
Although, there is a large body of evidence supporting a role for Hcy in the pathogenesis of 
PXFG, there are few studies on MTHFR mutation in this condition. Despite this, the findings 
have been universal: MTHFR mutation is not a risk factor for PXFG. Raised plasma Hcy is 
due to other factors in these patients. 
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Most MTHFR mutation research in glaucoma has been on POAG. Despite the inconsistent 
findings regarding Hcy, studies generally agree MTHFR mutation does not occur at an 
increased rate in POAG. Two studies85,102 have reported MTHFR C677T mutation is a risk 
factor for POAG. Both are from the same research group. It is unclear whether this data is 
from the same cohort of patients. 
Fewer studies have examined MTHFR mutation in NTG. For this reason, it is hard to make a 
sensible conclusion. At this stage, it seems MTHFR is not likely to be a risk factor for NTG 
but further research is needed. 
Two reports on PACG suggest an association. In both studies90,99 from the same group, the 
association was seen in only one ethnic subgroup (Pakistani Punjabi). The significance of 
this is uncertain without corroborating evidence from other groups examining different 
populations. 
7. Conclusion 
There is now a substantial body of literature on Hcy and glaucoma. Although there is 
general agreement that Hcy is raised in patients with PXFG, the findings have been less 
consistent for other types of chronic glaucoma. The reason for this is not entirely clear but 
may, in part, relate to study design and population differences. 
The findings in PXFG, and to a lesser extent with other chronic glaucoma, suggest therapeutic 
intervention might be an option in these patients. Plasma Hcy may be lowered by 
supplemental folate and vitamin B12: both are readily available, cheap and have few side 
effects. Benefit is likely to be derived from positive effects on vascular health, in particular 
optic nerve head perfusion. Reduced RGC apoptosis is another potential outcome. No studies 
have yet examined the effect of taking these supplements on glaucoma progression.  
With respect to treating raised Hcy in glaucoma, there are two areas of concern. First, the 
level of Hcy required to start treatment is ill defined. Although raised compared to control, 
most research quotes mean Hcy levels within the normal reference range. For example, our 
study75 found HHcy (female > 12 µmol/L; male > 14 µmol/L) in 27.6%, 30.6% and 29.4% of 
patients with PXFG, POAG and NTG respectively. This means two-thirds of patients return 
what is considered a normal Hcy reading. What do we do here? Options include treating 
only those with raised Hcy by laboratory definition, reducing the threshold for treatment or 
treating everyone irrespective of Hcy level. Clinical trials measuring glaucoma progression 
following folate and vitamin B12 supplementation relative to Hcy level will help define this 
better. 
Secondly, and more worrying, is the observation in the cardiovascular literature that 
interventions that reduce Hcy have little benefit.19 This is despite the consistent observation 
that raised Hcy is a risk factor for CVD. This points to a similar outcome in glaucoma 
research. However, glaucoma pathogenesis is multi-factorial and optic nerve head perfusion 
is only part of the story. Homocysteine, and strategies to lower it, can potentially have direct 
actions on the optic nerve (ie: apoptosis of RGCs) and structures that support it (ie: ECM 
remodeling). We have been encouraged by the outcomes in AD research29 showing benefit 
from supplemental folate and vitamin B12 intake.  
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